[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-335238-105":59,"doc-detail-335238-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","copy-number-alterations-in-metastatic-and-early-breast-tumours-prognostic-and-acquired-biomarkers-of-resistance-to-cdk46-inhibitors","Copy number alterations in metastatic and early breast tumours - prognostic and acquired biomarkers of resistance to CDK4/6 inhibitors","","Copy number alterations (CNA) accumulate as cancers progress from early to metastatic stages, and this study evaluates clinical relevance of metastasis-associated CNAs in metastatic breast cancers and early breast cancers. SNP-array profiling was performed on 926 metastatic biopsies from the SAFIR02-BREAST trial, with early-stage CNA profiles compared against TCGA, METABRIC, and PACS04 cohorts. Overall survival served as the endpoint. TERT amplification correlated with poor outcomes in ER+/HER2− metastatic disease, and post-treatment biopsies after CDK4/6 inhibitors identified CDK4 amplification linked to worse early outcomes, supporting actionable genomic resistance markers.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/copy-number-alterations-in-metastatic-and-early-breast-tumours-prognostic-and-acquired-biomarkers-of-resistance-to-cdk46-inhibitors/335238/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/copy-number-alterations-in-metastatic-and-early-breast-tumours-prognostic-and-acquired-biomarkers-of-resistance-to-cdk46-inhibitors/335238.png","ImageObject",300,407,{"name":92,"@type":93},"Levi","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-25","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is the study’s main goal regarding copy number alterations?","Question",{"text":113,"@type":114},"To analyze the clinical value of metastasis-associated copy number alterations when comparing metastatic breast cancers with early breast cancers.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How were copy number alteration profiles generated for metastatic and early breast cancers?",{"text":118,"@type":114},"Metastatic profiles used SNP-array on 926 biopsies from the SAFIR02-BREAST trial, while early-stage profiles were referenced from TCGA, METABRIC, and PACS04 cohorts.",{"name":120,"@type":111,"acceptedAnswer":121},"Which genomic alterations were linked to prognosis in ER+/HER2− disease?",{"text":122,"@type":114},"Focal TERT amplification was associated with poor outcome in ER+/HER2− metastatic breast cancer, and CDK4 amplification in post-treatment contexts was linked to poor outcome in early breast cancer.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},335238,1790158919,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":39,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":46,"preview_page_count":4},7971461740909,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","[www.nature.com/bjc](www.nature.com/bjc British)[ British](www.nature.com/bjc British) Journal of Cancer  \nARTICLE OPEN   \nGenetics and Genomics  \nCopy number alterations in metastatic and early breast tumours: prognostic and acquired biomarkers of resistance to CDK4/6 inhibitors  \nMarie-Paule Sablin 1,18, Pierre Gestraud 2,18, Sarah Flora Jonas3,4,18, Constance Lamy1, Magali Lacroix-Triki 5, Thomas Bachelot 6, Thomas Filleron7, Ludovic Lacroix 8,9, Alicia Tran-Dien 10, Pascal Jézéquel11, Marjorie Mauduit12, Janice Barros Monteiro 13,  \nMarta Jimenez 12, Stefan Michiels 3,4, Valery Attignon 14, Isabelle Soubeyran 15, Keltouma Driouch16, Nicolas Servant2, Christophe Le Tourneau 1,2, Maud Kamal 1,19, Fabrice André 17,19 and Ivan Bièche16,19 ✉  \n© The Author(s) 2024  \n\n|  | BACKGROUND: Copy number alterations (CNA) are acquired during the evolution of cancers from their early stage to metastatic stage. This study aims at analysing the clinical value of the identiﬁed metastasis-associated CNAs both in metastatic breast cancers (mBCs) and early breast cancers (eBCs) .\u003Cbr>METHODS: Single-nucleotide polymorphism (SNP)-array was performed on 926 biopsies from mBC patients, enrolled in SAFIR02-BREAST prospective trial. CNA proﬁles of eBCs from The Cancer Genome Atlas Breast Invasive Carcinoma (n = 770), Molecular Taxonomy of Breast Cancer International Consortium (n = 1620) and PACS04 trial (n = 243) cohorts were used as references for comparing mBCs and eBCs CNA proﬁles. Overall survival was the considered survival endpoint.\u003Cbr>RESULTS: Among the twenty-one genes frequently altered in ER + /HER2 − mBCs: focal ampliﬁcation of TERT was associated with poor outcome in the ER + /HER2 − mBC population. Among the ER + /HER2 − mBCs patients for whom CDK4/6 inhibitors information before biopsies collection was available: we identiﬁed seven genes on post-treatment biopsies, including the cyclindependent kinase 4 (CDK4), which was ampliﬁed in 9.8% of the ER + /HER2 − mBCs pretreated population, as compared to 1.5% in the ER + /HER2 − mBCs unpretreated population (P = 2.82E-04) as well as the 3 eBC populations. CDK4 ampliﬁcation was associated with poor outcome in the ER + /HER2 − eBCs.\u003Cbr>CONCLUSIONS: This study provides insights into the biology of mBCs and identiﬁes clinically useful genomic features for future |  |\n| --- | --- | --- |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n| improvement of breast cancer patient management. |  |  |\n|  | British Journal of Cancer (2024) 131:1060–1067; [https://doi.org/10.1038/s41416-024-02804-6](https://doi.org/10.1038/s41416-024-02804-6) |  |\n|  |  |  |\n\nINTRODUCTION  \nBreast cancer is the most common malignancy among women worldwide [1] . In western countries, more than 95% of breast cancers are diagnosed at the early stage. While the incidence of distant relapse is decreasing, 20–30% of patients with early breast cancer (eBCs) still die from metastatic disease [2] . Over the last two decades, signiﬁcant advances have been made in the management of breast cancer. Breast tumours are diverse in their natural history and their responsiveness to treatments. Indeed, breast  \ncancer is considered as a heterogeneous disease at a morphologic, immunohistochemical (IHC), and even molecular level [3] . A better understanding of the biology has led to overcome the historical classiﬁcation in three subgroups hormone receptor-positive (HR +), human epidermal growth factor receptor 2 overexpressed or ampliﬁed (HER2 +) and triple-negative breast cancer (TNBC), deﬁned by the lack of HRs and HER2 overexpression orampliﬁcation. Back in 2000, Sorlie et al. individualised ﬁve intrinsic molecular subtypes using gene expression proﬁling: luminal A,  \n1Department of Drug Development and Innovation (D3i), Institut Curie, Paris, France. 2Bioinformatics and Computational Systems Biology of Cancer, PSL Research University, Mines Pari","cbCainirI13iDGDe","https://ap.wps.com/l/cbCainirI13iDGDe","pdf",638215,"English","# Background\n# Methods\n# Results\n# Conclusions\n# Introduction","[{\"question\":\"What is the study’s main goal regarding copy number alterations?\",\"answer\":\"To analyze the clinical value of metastasis-associated copy number alterations when comparing metastatic breast cancers with early breast cancers.\"},{\"question\":\"How were copy number alteration profiles generated for metastatic and early breast cancers?\",\"answer\":\"Metastatic profiles used SNP-array on 926 biopsies from the SAFIR02-BREAST trial, while early-stage profiles were referenced from TCGA, METABRIC, and PACS04 cohorts.\"},{\"question\":\"Which genomic alterations were linked to prognosis in ER+/HER2− disease?\",\"answer\":\"Focal TERT amplification was associated with poor outcome in ER+/HER2− metastatic breast cancer, and CDK4 amplification in post-treatment contexts was linked to poor outcome in early breast cancer.\"}]","Copy number alterations in metastatic and early breast tumours - prognostic and acquired biomarkers of resistance to CDK4/6 inhibitors | PDF",1790010274]